A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Tiral of Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection (VDJ001) in the Treatment of Idiopathic Multicentric Castleman Disease (iMCD)
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).
• Age ≥18 years, regardless of gender;
• Biopsy or central pathological examination confirmed measurable, symptomatic iMCD (diagnosed according to the guideline for the diagnosis and treatment of Castleman disease in China (2025 )), with the patient presenting at least one of the following symptoms: fatigue, anorexia, fever, or weight loss;
• Clinical laboratory values within 4 weeks prior to the first dose meeting the following criteria:
‣ Absolute neutrophil count (ANC) ≥1.0×10⁹/L;
⁃ Platelet count (PLT) ≥75×10⁹/L;
⁃ Alanine aminotransferase (ALT) \<2.5×ULN;
⁃ Total bilirubin (TBIL) \<2.5×ULN;
⁃ Serum creatinine (SCr) ≤3.0 mg/dL (265 μmol/L).
• ECOG-PS performance status score of 0, 1, or 2;
• If corticosteroids are used (e.g., prednisone), the dose should not exceed 1 mg/kg/day (or equivalent dose of other corticosteroids, see appendix), and must have been stable or reduced within 4 weeks prior to the first dose;
• Patients of childbearing potential (male and female) must agree to use effective contraception during the trial and for 6 months after the last dose; males must not donate sperm and females must not donate oocyte during this period;
• The patient (or their legal guardian or impartial witness) must sign the informed consent form before any study-specific procedures are performed, indicating understanding of the study purpose and required procedures, and voluntary participation in the study.